MKI67 and neoplasm: We found that the tumours in the safranal-treated group were significantly smaller than those in the control group, while the intracranial tumours in the safranal combined with temozolomide group were significantly smaller than those in the temozolomide monotherapy group (Figures 9A, B).The immunohistochemical results showed that the expression of Ki-67 in tumour cells of safranal-treated mice was significantly lower than that tumour cells of the control mice (Figures 9C, D).